EUR 139.9
(-3.38%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 528.37 Million EUR | 40.96% |
2022 | 374.84 Million EUR | 1.95% |
2021 | 367.66 Million EUR | 228.94% |
2020 | 111.77 Million EUR | -42.74% |
2019 | 195.21 Million EUR | 42.57% |
2018 | 136.93 Million EUR | 132.7% |
2017 | 58.84 Million EUR | 117.08% |
2016 | 27.1 Million EUR | -32.76% |
2015 | 40.31 Million EUR | 326.46% |
2014 | 9.45 Million EUR | 23.71% |
2013 | 7.64 Million EUR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 517.32 Million EUR | 10.18% |
2024 Q1 | 469.53 Million EUR | -11.14% |
2023 Q1 | 412.66 Million EUR | 10.09% |
2023 Q2 | 482.08 Million EUR | 16.82% |
2023 Q4 | 528.37 Million EUR | 13.1% |
2023 FY | 528.37 Million EUR | 40.96% |
2023 Q3 | 467.15 Million EUR | -3.1% |
2022 Q4 | 374.84 Million EUR | -8.09% |
2022 Q1 | 377.78 Million EUR | 2.75% |
2022 Q2 | 410.88 Million EUR | 8.76% |
2022 FY | 374.84 Million EUR | 1.95% |
2022 Q3 | 407.84 Million EUR | -0.74% |
2021 Q4 | 367.66 Million EUR | 2.98% |
2021 Q3 | 357.02 Million EUR | 1.26% |
2021 Q2 | 352.59 Million EUR | -2.9% |
2021 Q1 | 363.11 Million EUR | 224.87% |
2021 FY | 367.66 Million EUR | 228.94% |
2020 FY | 111.77 Million EUR | -42.74% |
2020 Q4 | 111.77 Million EUR | -55.16% |
2020 Q3 | 249.26 Million EUR | 1.51% |
2020 Q2 | 245.55 Million EUR | 2.09% |
2020 Q1 | 240.52 Million EUR | 23.21% |
2019 Q3 | 212.96 Million EUR | 1.42% |
2019 Q4 | 195.21 Million EUR | -8.33% |
2019 FY | 195.21 Million EUR | 42.57% |
2019 Q1 | 154 Million EUR | 12.47% |
2019 Q2 | 209.97 Million EUR | 36.35% |
2018 Q1 | 66.29 Million EUR | 12.66% |
2018 FY | 136.93 Million EUR | 132.7% |
2018 Q4 | 136.93 Million EUR | -2.02% |
2018 Q3 | 139.75 Million EUR | 7.09% |
2018 Q2 | 130.49 Million EUR | 96.85% |
2017 Q3 | 43.95 Million EUR | 51.74% |
2017 Q2 | 28.96 Million EUR | -15.52% |
2017 Q4 | 58.84 Million EUR | 33.87% |
2017 FY | 58.84 Million EUR | 117.08% |
2017 Q1 | 34.28 Million EUR | 26.5% |
2016 Q2 | 43.3 Million EUR | 0.0% |
2016 Q1 | - EUR | -100.0% |
2016 FY | 27.1 Million EUR | -32.76% |
2016 Q4 | 27.1 Million EUR | -47.26% |
2016 Q3 | 51.4 Million EUR | 18.7% |
2015 Q1 | - EUR | 0.0% |
2015 Q4 | 40.31 Million EUR | 0.0% |
2015 FY | 40.31 Million EUR | 326.46% |
2014 FY | 9.45 Million EUR | 23.71% |
2013 FY | 7.64 Million EUR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Newron Pharmaceuticals S.p.A. | 55.8 Million EUR | -846.897% |